# Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans

> **NCT05883306** · PHASE1 · COMPLETED · sponsor: **Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.** · enrollment: 6 (actual)

## Conditions studied

- Healthy Subjects
- Pharmacokinetics of 14C-labeled of LXI-15028

## Interventions

- **DRUG:** [14C]LXI-15028

## Key facts

- **NCT ID:** NCT05883306
- **Lead sponsor:** Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-30
- **Primary completion:** 2022-07-21
- **Final completion:** 2022-12-23
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05883306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05883306, "Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05883306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*